CryoLife to Receive $2.25 Million to Settle Dispute
CryoLife, Inc. has settled an outstanding insurance coverage dispute for $2.25 million. The dispute involved losses stemming from amounts paid in 2005 by the Company. In resolving the dispute, no party admitted any liability.
Steven G. Anderson, President and Chief Executive Officer stated, "We believe that the settlement of this dispute was in the best interests of our shareholders and are pleased to have this matter behind us. The settlement strengthens our financial position and reinforces our belief that we will not have to complete a financing to fund our day-to-day operations."
Investors and other interested parties are referred to the Company's Form 8-K filed with the Securities and Exchange Commission on September 29, 2006.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Sysmex and Epigenomics AG Announce Strategic R&D Collaboration in Colorectal Cancer Diagnostics - Parties entered into negotiations for a non-exclusive IVD license to mSEPT9 colorectal cancer blood test
Genentech to set up Singapore's first Microbial-Based Biopharmaceutical Manufacturing Facility - Fourth Biologics Facility in Less Than 2 Years Helps Establish Singapore as a Serious Player in Biologics Manufacturing
Arakis completes Phase I trials of AD 337 in fibromyalgia syndrome
ABRAXANE meets primary endpoint in phase 3 trial for advanced non-small cell lung cancer
Oncolytics Biotech Inc. has been granted patent for extracting virus from cell culture
Researchers identify genes linked to chemoresistance
